Cutia Therapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	250.33	279.62	137.62	11.37	2.04
Revenue Growth (YoY)	25.89%	103.17%	1110.83%	457.70%	-
Cost of Revenue	125.14	136.15	66.62	3.43	0.43
Gross Profit	125.19	143.46	71.01	7.94	1.61
Selling, General & Admin	390.35	405.53	394.2	136.39	71.04
Research & Development	178.92	199.05	215.71	180.76	110.56
Operating Expenses	576.88	605.01	610.66	317.14	181.6
Operating Income	-451.69	-461.54	-539.65	-309.2	-179.99
Interest Expense	-10.96	-10.86	-4.48	-1.73	-0.56
Interest & Investment Income	7.65	11.81	23.41	17.37	6.11
Currency Exchange Gain (Loss)	0.34	2.34	20.8	73.98	-23.03
Other Non Operating Income (Expenses)	-31.56	3.32	-11.82	-16.83	3.4
EBT Excluding Unusual Items	-486.23	-454.93	-511.74	-236.41	-194.06
Gain (Loss) on Sale of Investments	16.27	21.99	2.47	7.68	-5.2
Gain (Loss) on Sale of Assets	-1.33	-0.36	-0.25	-	-
Other Unusual Items	-0.99	-0.51	-1,454	-327.1	-120.33
Pretax Income	-472.27	-433.81	-1,964	-555.84	-319.58
Net Income	-472.27	-433.81	-1,964	-555.84	-319.58
Net Income to Common	-472.27	-433.81	-1,964	-555.84	-319.58
Shares Outstanding (Basic)	314	307	205	80	80
Shares Outstanding (Diluted)	314	307	205	80	80
Shares Change (YoY)	2.95%	50.13%	155.62%	-	-
EPS (Basic)	-1.50	-1.41	-9.60	-6.94	-3.99
EPS (Diluted)	-1.50	-1.41	-9.60	-6.94	-3.99
Free Cash Flow	-389.88	-465.56	-437.04	-370.54	-184.2
Free Cash Flow Per Share	-1.24	-1.52	-2.14	-4.63	-2.30
Gross Margin	50.01%	51.31%	51.60%	69.84%	79.00%
Operating Margin	-180.44%	-165.06%	-392.13%	-2720.43%	-8831.45%
Profit Margin	-188.66%	-155.15%	-1426.91%	-4890.34%	-15681.11%
Free Cash Flow Margin	-155.75%	-166.50%	-317.56%	-3260.10%	-9038.08%
EBITDA	-421.41	-432.92	-508.8	-298.43	-174.06
EBITDA Margin	-168.34%	-154.83%	-	-	-
D&A For EBITDA	30.27	28.62	30.85	10.78	5.93
EBIT	-451.69	-461.54	-539.65	-309.2	-179.99
EBIT Margin	-180.44%	-165.06%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.